Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Sanofi announces its biggest China investment deal amid China-EU trade tensions
    Finance

    Sanofi announces its biggest China investment deal amid China-EU trade tensions

    Published by Global Banking & Finance Review®

    Posted on December 3, 2024

    1 min read

    Last updated: January 28, 2026

    This image illustrates the recent uptick in oil prices, reflecting investor optimism regarding China's economic recovery. The graphic aligns with the article's focus on oil market trends amid geopolitical factors and China's growth policies.
    Graph showing rising oil prices as investors eye China's economic recovery - Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Sanofi announces a €1 billion investment in Beijing, marking its largest in China amid China-EU trade tensions.

    Sanofi's Largest China Investment Amid EU Trade Tensions

    SHANGHAI (Reuters) -Sanofi plans to invest around 1 billion euros ($1.05 billion) to build a new insulin production base in Beijing, which will mark the French drugmaker's largest single investment in China, the company said on Monday.

    The site, which will be in the Beijing Economic and Technological Development Zone, will be Sanofi’s fourth production and supply base in China, Sanofi said in its official WeChat account.

    China is seeking to strengthen economic ties with individual members of the European Union, even as its trade relations with the 27-nation bloc soured over issues including accusations of Chinese government subsidies to the electric vehicle industry.

    In a Monday meeting with Sanofi Chairman Frederic Oudea in Beijing, Chinese Commerce Minister Wang Wentao said China will support all businesses equally in technological innovation and participating in market competition, a ministry statement said.

    China will continue to open up its market, and is committed to building a business environment for companies including Sanofi to operate and develop with "peace of mind," Wang added.

    ($1 = 0.9500 euro)

    (Reporting by Brenda Goh, additional reporting by Beijing Newsroom; Editing by Louise Heavens and Jonathan Oatis)

    Key Takeaways

    • •Sanofi plans a €1 billion investment in Beijing.
    • •This is Sanofi's largest single investment in China.
    • •The new site will be in the Beijing Economic Zone.
    • •China aims to strengthen ties with EU members.
    • •China supports equal business opportunities.

    Frequently Asked Questions about Sanofi announces its biggest China investment deal amid China-EU trade tensions

    1What is the main topic?

    The article discusses Sanofi's €1 billion investment in a new insulin production base in Beijing amid China-EU trade tensions.

    2Why is Sanofi investing in China?

    Sanofi is investing to expand its production capabilities and strengthen its presence in the Chinese market.

    3How does this investment relate to China-EU trade?

    The investment comes amid strained China-EU trade relations, highlighting China's efforts to strengthen ties with EU members.

    More from Finance

    Explore more articles in the Finance category

    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    View All Finance Posts
    Previous Finance PostFactbox-As CEO Tavares leaves Stellantis, market speculates on successor
    Next Finance PostMorning Bid: Notre-Dame rebuilt, as Paris nears collapse